Annual Total Liabilities
$36.46 M
+$9.93 M+37.41%
31 December 2023
Summary:
Celldex Therapeutics annual total liabilities is currently $36.46 million, with the most recent change of +$9.93 million (+37.41%) on 31 December 2023. During the last 3 years, it has risen by +$9.97 million (+37.67%). CLDX annual total liabilities is now -69.09% below its all-time high of $117.93 million, reached on 31 December 2016.CLDX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$37.27 M
+$5.35 M+16.75%
01 September 2024
Summary:
Celldex Therapeutics quarterly total liabilities is currently $37.27 million, with the most recent change of +$5.35 million (+16.75%) on 01 September 2024. Over the past year, it has increased by +$3.74 million (+11.14%). CLDX quarterly total liabilities is now -68.39% below its all-time high of $117.93 million, reached on 31 December 2016.CLDX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CLDX Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +37.4% | +11.1% |
| 3 y3 years | +37.7% | +58.7% |
| 5 y5 years | +14.8% | +22.4% |
CLDX Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +44.8% | -1.6% | +71.2% |
| 5 y | 5 years | at high | +44.8% | -1.6% | +71.2% |
| alltime | all time | -69.1% | +2178.5% | -68.4% | +2767.2% |
Celldex Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $37.27 M(+16.7%) |
| June 2024 | - | $31.93 M(+5.6%) |
| Mar 2024 | - | $30.23 M(-17.1%) |
| Dec 2023 | $36.46 M(+37.4%) | $36.46 M(+8.7%) |
| Sept 2023 | - | $33.54 M(+54.0%) |
| June 2023 | - | $21.77 M(-0.0%) |
| Mar 2023 | - | $21.78 M(-17.9%) |
| Dec 2022 | $26.53 M(+5.4%) | $26.53 M(+11.4%) |
| Sept 2022 | - | $23.81 M(-37.1%) |
| June 2022 | - | $37.87 M(+46.0%) |
| Mar 2022 | - | $25.94 M(+3.0%) |
| Dec 2021 | $25.18 M(-4.9%) | $25.18 M(+7.2%) |
| Sept 2021 | - | $23.49 M(+5.5%) |
| June 2021 | - | $22.27 M(-10.6%) |
| Mar 2021 | - | $24.90 M(-6.0%) |
| Dec 2020 | $26.48 M(-8.4%) | $26.48 M(+2.7%) |
| Sept 2020 | - | $25.80 M(+12.4%) |
| June 2020 | - | $22.96 M(-20.3%) |
| Mar 2020 | - | $28.80 M(-0.4%) |
| Dec 2019 | $28.91 M(-9.0%) | $28.91 M(-5.1%) |
| Sept 2019 | - | $30.46 M(-6.6%) |
| June 2019 | - | $32.62 M(-6.5%) |
| Mar 2019 | - | $34.88 M(+9.9%) |
| Dec 2018 | $31.75 M(-59.9%) | $31.75 M(-20.9%) |
| Sept 2018 | - | $40.15 M(-20.2%) |
| June 2018 | - | $50.33 M(-12.2%) |
| Mar 2018 | - | $57.29 M(-27.7%) |
| Dec 2017 | $79.25 M(-32.8%) | $79.25 M(-21.0%) |
| Sept 2017 | - | $100.27 M(-12.5%) |
| June 2017 | - | $114.61 M(+2.1%) |
| Mar 2017 | - | $112.21 M(-4.8%) |
| Dec 2016 | $117.93 M(+148.4%) | $117.93 M(+238.3%) |
| Sept 2016 | - | $34.85 M(-4.5%) |
| June 2016 | - | $36.50 M(-12.9%) |
| Mar 2016 | - | $41.90 M(-11.8%) |
| Dec 2015 | $47.48 M(+30.6%) | $47.48 M(+39.6%) |
| Sept 2015 | - | $34.01 M(-8.9%) |
| June 2015 | - | $37.34 M(+16.1%) |
| Mar 2015 | - | $32.15 M(-11.6%) |
| Dec 2014 | $36.35 M(+33.2%) | $36.35 M(+12.6%) |
| Sept 2014 | - | $32.29 M(+0.0%) |
| June 2014 | - | $32.28 M(+20.2%) |
| Mar 2014 | - | $26.85 M(-1.6%) |
| Dec 2013 | $27.30 M(-8.3%) | $27.30 M(+12.8%) |
| Sept 2013 | - | $24.21 M(+26.5%) |
| June 2013 | - | $19.14 M(-35.0%) |
| Mar 2013 | - | $29.42 M(-1.2%) |
| Dec 2012 | $29.77 M(+1.7%) | $29.77 M(+3.3%) |
| Sept 2012 | - | $28.82 M(+4.5%) |
| June 2012 | - | $27.58 M(-4.4%) |
| Mar 2012 | - | $28.85 M(-1.4%) |
| Dec 2011 | $29.27 M(-15.6%) | $29.27 M(+5.4%) |
| Sept 2011 | - | $27.77 M(+4.9%) |
| June 2011 | - | $26.47 M(-0.6%) |
| Mar 2011 | - | $26.62 M(-23.3%) |
| Dec 2010 | $34.69 M(-47.9%) | $34.69 M(-42.0%) |
| Sept 2010 | - | $59.79 M(-2.9%) |
| June 2010 | - | $61.57 M(-3.8%) |
| Mar 2010 | - | $63.99 M(-3.9%) |
| Dec 2009 | $66.60 M(+28.9%) | $66.60 M(+32.3%) |
| Sept 2009 | - | $50.34 M(+0.5%) |
| June 2009 | - | $50.11 M(-3.1%) |
| Mar 2009 | - | $51.69 M(+0.1%) |
| Dec 2008 | $51.66 M(+391.7%) | $51.66 M(-6.7%) |
| Sept 2008 | - | $55.35 M(-2.7%) |
| June 2008 | - | $56.91 M(+350.2%) |
| Mar 2008 | - | $12.64 M(+20.3%) |
| Dec 2007 | $10.51 M(-82.3%) | $10.51 M(-81.7%) |
| Sept 2007 | - | $57.35 M(-1.2%) |
| June 2007 | - | $58.04 M(+0.6%) |
| Mar 2007 | - | $57.71 M(-2.7%) |
| Dec 2006 | $59.32 M | $59.32 M(+5.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2006 | - | $56.35 M(+1.1%) |
| June 2006 | - | $55.75 M(+1.1%) |
| Mar 2006 | - | $55.12 M(+254.2%) |
| Dec 2005 | $15.56 M(+110.4%) | $15.56 M(+1.2%) |
| Sept 2005 | - | $15.38 M(-0.3%) |
| June 2005 | - | $15.43 M(+136.9%) |
| Mar 2005 | - | $6.51 M(-12.0%) |
| Dec 2004 | $7.40 M(+118.5%) | $7.40 M(+78.0%) |
| Sept 2004 | - | $4.15 M(+24.8%) |
| June 2004 | - | $3.33 M(+13.2%) |
| Mar 2004 | - | $2.94 M(-13.1%) |
| Dec 2003 | $3.39 M(-12.9%) | $3.39 M(+4.2%) |
| Sept 2003 | - | $3.25 M(-20.2%) |
| June 2003 | - | $4.07 M(-1.2%) |
| Mar 2003 | - | $4.12 M(+5.9%) |
| Dec 2002 | $3.89 M(-52.7%) | $3.89 M(+3.0%) |
| Sept 2002 | - | $3.78 M(-46.3%) |
| June 2002 | - | $7.04 M(-4.1%) |
| Mar 2002 | - | $7.34 M(-10.7%) |
| Dec 2001 | $8.22 M(-14.7%) | $8.22 M(+2.2%) |
| Sept 2001 | - | $8.04 M(-7.0%) |
| June 2001 | - | $8.64 M(+10.3%) |
| Mar 2001 | - | $7.83 M(-18.7%) |
| Dec 2000 | $9.63 M(+290.0%) | $9.63 M(+67.4%) |
| Sept 2000 | - | $5.75 M(+18.2%) |
| June 2000 | - | $4.87 M(-10.3%) |
| Mar 2000 | - | $5.43 M(+119.7%) |
| Dec 1999 | $2.47 M(-35.9%) | $2.47 M(+2.9%) |
| Sept 1999 | - | $2.40 M(-14.3%) |
| June 1999 | - | $2.80 M(-24.3%) |
| Mar 1999 | - | $3.70 M(-3.9%) |
| Dec 1998 | $3.85 M(+10.0%) | $3.85 M(-3.7%) |
| Sept 1998 | - | $4.00 M(+48.1%) |
| June 1998 | - | $2.70 M(-10.0%) |
| Mar 1998 | - | $3.00 M(-14.3%) |
| Dec 1997 | $3.50 M(+118.8%) | $3.50 M(-7.9%) |
| Sept 1997 | - | $3.80 M(+171.4%) |
| June 1997 | - | $1.40 M(+7.7%) |
| Mar 1997 | - | $1.30 M(-18.8%) |
| Dec 1996 | $1.60 M(-36.0%) | $1.60 M(+23.1%) |
| Sept 1996 | - | $1.30 M(-13.3%) |
| June 1996 | - | $1.50 M(-21.1%) |
| Mar 1996 | - | $1.90 M(-24.0%) |
| Dec 1995 | $2.50 M(-19.4%) | $2.50 M(+25.0%) |
| Sept 1995 | - | $2.00 M(-13.0%) |
| June 1995 | - | $2.30 M(-17.9%) |
| Mar 1995 | - | $2.80 M(-9.7%) |
| Dec 1994 | $3.10 M(-22.5%) | $3.10 M(-31.1%) |
| Sept 1994 | - | $4.50 M(+9.8%) |
| June 1994 | - | $4.10 M(-2.4%) |
| Mar 1994 | - | $4.20 M(+5.0%) |
| Dec 1993 | $4.00 M(+66.7%) | $4.00 M(+37.9%) |
| Sept 1993 | - | $2.90 M(+16.0%) |
| June 1993 | - | $2.50 M(-7.4%) |
| Mar 1993 | - | $2.70 M(-12.9%) |
| Dec 1992 | $2.40 M(-29.4%) | - |
| Oct 1992 | - | $3.10 M(-8.8%) |
| July 1992 | - | $3.40 M(0.0%) |
| Apr 1992 | - | $3.40 M(+21.4%) |
| Apr 1992 | $3.40 M(+21.4%) | - |
| Jan 1992 | - | $2.80 M(-3.4%) |
| Oct 1991 | - | $2.90 M(+3.6%) |
| July 1991 | - | $2.80 M(0.0%) |
| Apr 1991 | $2.80 M(+12.0%) | $2.80 M(+33.3%) |
| Jan 1991 | - | $2.10 M(0.0%) |
| Oct 1990 | - | $2.10 M(-32.3%) |
| July 1990 | - | $3.10 M(+24.0%) |
| Apr 1990 | $2.50 M(-47.9%) | $2.50 M(+31.6%) |
| Jan 1990 | - | $1.90 M(-60.4%) |
| Apr 1989 | $4.80 M(+29.7%) | $4.80 M(+29.7%) |
| Apr 1988 | $3.70 M(-11.9%) | $3.70 M(-11.9%) |
| Apr 1987 | $4.20 M(-26.3%) | $4.20 M(-26.3%) |
| Apr 1986 | $5.70 M | $5.70 M |
FAQ
- What is Celldex Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Celldex Therapeutics?
- What is Celldex Therapeutics annual total liabilities year-on-year change?
- What is Celldex Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Celldex Therapeutics?
- What is Celldex Therapeutics quarterly total liabilities year-on-year change?
What is Celldex Therapeutics annual total liabilities?
The current annual total liabilities of CLDX is $36.46 M
What is the all time high annual total liabilities for Celldex Therapeutics?
Celldex Therapeutics all-time high annual total liabilities is $117.93 M
What is Celldex Therapeutics annual total liabilities year-on-year change?
Over the past year, CLDX annual total liabilities has changed by +$9.93 M (+37.41%)
What is Celldex Therapeutics quarterly total liabilities?
The current quarterly total liabilities of CLDX is $37.27 M
What is the all time high quarterly total liabilities for Celldex Therapeutics?
Celldex Therapeutics all-time high quarterly total liabilities is $117.93 M
What is Celldex Therapeutics quarterly total liabilities year-on-year change?
Over the past year, CLDX quarterly total liabilities has changed by +$3.74 M (+11.14%)